文献速递头痛与眩晕

利扎曲普坦治疗前庭性偏头痛发作的随机临床试验

Rizatriptan vs Placebo for Attacks of Vestibular Migraine: A Randomized Clinical Trial.
PubMed 文献 · JAMA Neurol · 2025-01-01

这项双盲随机对照试验纳入222例成人前庭性偏头痛患者,其中134例治疗了307次发作,对240次中重度发作分析显示,利扎曲普坦10mg在1小时改善眩晕或头昏方面与安慰剂无差异,24小时仅对头昏和运动敏感有中等效应,不推荐用于前庭性偏头痛发作。

要点

  • 利扎曲普坦10mg治疗前庭性偏头痛发作在1小时主要终点与安慰剂无差异。
  • 24小时对头昏和运动敏感有中等效应,但整体获益有限。
  • 未发生严重不良事件,两组的补救药物使用比例均为26.4%。

核心结论

  • 利扎曲普坦治疗前庭性偏头痛发作在1小时无效,24小时症状改善有限,结果不支持使用。

研究设计与样本

  • 双盲随机对照试验,2014年12月至2020年7月在2个三级神经耳科中心进行,纳入成人前庭性偏头痛患者。
  • 共222例参与者(平均年龄42.3岁,70.7%为女性),134例(60.4%)活跃期患者按2:1随机接受利扎曲普坦10mg或安慰剂,治疗最多3次发作。

主要发现

  • 1小时眩晕从中重度降至无或轻度:利扎曲普坦组73/151次(48.3%),安慰剂组50/88次(56.8%),OR 0.71(95%CI 0.42-1.21)。
  • 1小时头昏/头晕改善:利扎曲普坦组29/151次(19.2%),安慰剂组11/89次(12.4%),OR 1.69(95%CI 0.80-3.57)。
  • 所有次要结局在1小时均无差异;24小时利扎曲普坦对头昏/头晕(OR 2.65)和运动敏感(OR 3.58)有中等效应。
  • 事后分析所有治疗发作发现,24小时利扎曲普坦对头痛和畏光/畏声有中等效应;治疗满意度结果不明确,生活质量结果混合。

关键数值与推荐

  • 主要结局为1小时眩晕和头昏/头晕从中重度降至无或轻度的发作百分比,两组无显著差异。

临床怎么用

  • 不推荐使用利扎曲普坦治疗前庭性偏头痛发作。
  • 24小时对头昏和运动敏感的有限获益需结合个体情况权衡。

局限性

  • 原文未报告

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Vestibular migraine has no established treatments. OBJECTIVE: To test the efficacy of rizatriptan for treating vestibular migraine attacks. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, randomized clinical trial of rizatriptan vs placebo was conducted from December 2014 through July 2020 (data analyses in 2021 and sensitivity analyses in 2022 and 2024) at 2 tertiary neurotologic centers. Adults with vestibular migraine were included. INTERVENTION: All participants underwent prospective observation to confirm diagnosis and illness activity and were then randomized in a 2:1 ratio to receive rizatriptan 10 mg or placebo to treat up to 3 vestibular migraine attacks per participant. MAIN OUTCOMES AND MEASURES: Participants rated symptoms as absent, mild, moderate, or severe at scheduled intervals. Primary outcomes were the percentage of attacks with reductions in vertigo and unsteadiness/dizziness from moderate or severe to absent or mild at 1 hour. Secondary outcomes were the percentage of attacks with complete resolution of vestibular symptoms at 1 hour; reductions in headache and associated symptoms at 1 hour; use of rescue medications after 1 hour; reductions in vestibular, headache, and associated symptoms at 24 hours without rescue medications; treatment satisfaction and quality of life at 48 hours; and rates of serious adverse effects and discontinuation due to adverse effects. RESULTS: Of 222 total participants (mean [SD] age, 42.3 [11.7] years; 70.7% were women), 134 (60.4%) with active illness treated 307 attacks. Efficacy was tested using 240 attacks with vestibular symptoms rated as moderate or severe when participants took study drug. At 1 hour, rizatriptan did not differ from placebo for reducing vertigo (73/151 [48.3%] vs 50/88 [56.8%] attacks; odds ratio [OR], 0.71 [95% CI, 0.42-1.21]), unsteadiness/dizziness (29/151 [19.2%] vs 11/89 [12.4%] attacks; OR, 1.69 [95% CI, 0.80-3.57]), or any secondary outcomes. Similar percentages of participants in rizatriptan and placebo groups (26.4% for both groups) added rescue remedies after 1 hour. At 24 hours, rizatriptan had medium effects over placebo for unsteadiness/dizziness (OR, 2.65) and motion sensitivity (OR, 3.58). Post hoc analyses of all treated attacks found a medium effect favoring rizatriptan for headache and photophobia or phonophobia at 24 hours. Treatment satisfaction was equivocal. Quality of life was mixed. No participants experienced serious adverse effects or discontinued treatment for adverse effects. CONCLUSIONS AND RELEVANCE: In this study, rizatriptan was ineffective at 1 hour for treating vestibular migraine attacks and had limited benefit on symptoms at 24 hours. Findings do not support using rizatriptan for vestibular migraine attacks. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02447991.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Staab JP, Eggers SDZ, Jen JC, et al. Rizatriptan vs Placebo for Attacks of Vestibular Migraine: A Randomized Clinical Trial. JAMA Neurol. 2025. PMID: 40354049. doi:10.1001/jamaneurol.2025.1006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。